Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8 (11), e1638212

Trial Watch: Dendritic Cell Vaccination for Cancer Immunotherapy


Trial Watch: Dendritic Cell Vaccination for Cancer Immunotherapy

Jenny Sprooten et al. Oncoimmunology.


Dendritic- cells (DCs) have received considerable attention as potential targets for the development of anticancer vaccines. DC-based anticancer vaccination relies on patient-derived DCs pulsed with a source of tumor-associated antigens (TAAs) in the context of standardized maturation-cocktails, followed by their reinfusion. Extensive evidence has confirmed that DC-based vaccines can generate TAA-specific, cytotoxic T cells. Nonetheless, clinical efficacy of DC-based vaccines remains suboptimal, reflecting the widespread immunosuppression within tumors. Thus, clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies. Here, we summarize the most recent preclinical/clinical development of anticancer DC vaccination and discuss future perspectives for DC-based vaccines in immuno-oncology.

Keywords: Antigen cross-presentation; DAMPs; TLR signaling; clinical trial; immune checkpoint blockers; plasmacytoid dendritic cells; tumor-infiltrating lymphocytes.

Similar articles

See all similar articles

Cited by 1 PubMed Central articles

LinkOut - more resources